HAYA's lead development candidate (HTX-001) is a modified antisense oligonucleotide (ASO) targeting the lncRNA Wisper, a cardiac myofibroblast enriched driver of fibrosis. Preclinical assessment has demonstrated the ability of HTX-001 to halt and potentially reverse the fibrotic processes underlying heart failure.
The non-coding portion of the genome, known as ‘dark matter’, is dynamically active, generating thousands of therapeutically unexplored long non-coding RNAs
IncRNAs are a unique class of regulatory molecules that bridge the analog world of proteins with the digital world of nucleic acids both DNA & RNA to regulate disease associated cellular processes in response to the environment
IncRNAs process and integrate environmental signals to modulate the epigenome, regulating key drivers of chronic disease processes associated with fibrosis and aging
HAYA has developed proprietary tools and methods to interrogate lncRNA biology, identifying exquisitely tissue- and cell-type specific therapeutic targets
Specific lncRNAs are important regulators of the resting fibroblast to myofibroblast conversion, resulting in fibrosis and disease
HAYA is utilizing emerging RNA-targeting modalities, such as modified antisense oligonucleotides (ASOs), to target and inhibit proprietary lncRNAs to prevent and reverse fibrosis
The rapid development of anti-fibrotic therapeutics that are safe, effective and accessible.
Our proprietary drug discovery engine enables us to discover and generate a pipeline of lncRNA targeting anti-fibrotic candidates for many tissues including lung, kidney, liver and the tumor microenvironment. These lead targets have the potential for significantly greater efficacy, safety and accessibility than existing treatments
HAYA's initial focus is the development of precision genomic medicines for fibrotic diseases and other serious health conditions associated with aging.
HAYA is utilizing DiscoverHAYA™️ to identify lead candidates for other fibrotic indications in tissues including the lung, kidney, liver, skin and tumor microenvironment.
Click here to learn more about HAYA leading therapeutics candidates.
